SUPERNUS PHARMACEUTICALS, INC. 8-K

What Happened Supernus Pharmaceuticals, Inc. (SUPN) filed an 8-K (dated January 28, 2026) reporting that on January 22, 2026 it entered into a First Amendment to the Agreement and Plan of Merger dated September 12, 2018. The Amendment, executed with Reich Consulting Group, Inc. as the Securityholder Representative, relates to the timing and payment of certain milestone payments under the original Merger Agreement. The Amendment is filed as Exhibit 10.1 to the Form 8-K.

Key Details

• Amendment date: January 22, 2026.
• Original Merger Agreement date: September 12, 2018.
• Counterparty in the amendment: Reich Consulting Group, Inc., as Securityholder Representative.
• Subject matter: revised timing and payment terms for specified milestone obligations under the Merger Agreement.
• Exhibit 10.1 is filed with the 8-K; certain confidential portions were omitted per Regulation S-K.

Why It Matters This amendment changes when and how certain merger-related milestone payments will be made, which directly affects the company’s contractual obligations arising from the 2018 acquisition. For investors, that can influence the timing of cash outflows and the company’s liability profile tied to the merger—important for assessing near-term cash needs and the financial impact of the acquisition agreement. Review Exhibit 10.1 for the full amendment text (note limited confidential redactions).